drugset / Trial / NCT01224028

A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients

NCT01224028

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.

Timeline

Start
2010-11
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.05 mg/kg Oral